← All trials
NCT06551246
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 27, 2024
- Primary completion
- Dec 1, 2027
- Completion date
- Dec 1, 2027
- First posted
- Aug 13, 2024
- Last posted
- Sep 26, 2024
- Enrollment
- 236
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Aarhus UniversityLead sponsor
- Gødstrup HospitalOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.